Literature DB >> 18245597

Proximal tibial osteochondromas in patients with fibrodysplasia ossificans progressiva.

Gregory K Deirmengian1, Nader M Hebela, Michael O'Connell, David L Glaser, Eileen M Shore, Frederick S Kaplan.   

Abstract

BACKGROUND: Fibrodysplasia ossificans progressiva is a rare autosomal dominant disorder characterized by congenital malformation of the great toes and by progressive heterotopic ossification of skeletal muscle and soft connective tissues. The disorder is caused by a recurrent missense mutation in the glycine-serine activation domain of activin A receptor type I, a bone morphogenetic protein (BMP) type-I receptor, in all classically affected individuals. Osteochondromas of the proximal part of the tibia are benign osteochondral neoplasms or orthotopic lesions of skeletal remodeling associated with dysregulated BMP signaling and have been considered an atypical feature of fibrodysplasia ossificans progressiva, but they may be underdiagnosed because of their often asymptomatic nature. The purpose of the present study was to determine the prevalence and characteristics of proximal tibial osteochondromas in individuals who have fibrodysplasia ossificans progressiva.
METHODS: Over a period of thirty months, we evaluated all patients with new and established fibrodysplasia ossificans progressiva for the presence of proximal tibial osteochondromas on the basis of medical history, physical examination, and radiographic studies. We quantified the prevalence of osteochondromas and characterized the types of osteochondromas to identify relevant trends.
RESULTS: Ninety-six patients (including fifty-two female patients and forty-four male patients) with fibrodysplasia ossificans progressiva were evaluated on the basis of a history and physical examination. Plain radiographs were available for sixty-seven patients. Ninety percent of all patients had osteochondroma of the proximal part of the tibia. These lesions usually were asymptomatic, most commonly were bilateral, and typically were located at the pes anserinus. Seventy-five percent of the lesions were pedunculated, and 25% were sessile.
CONCLUSIONS: Proximal tibial osteochondromas are a common phenotypic feature of fibrodysplasia ossificans progressiva, a finding that expands the recognized consequences of recurrent activating mutations in activin A receptor type I to include not only congenital skeletal malformations and heterotopic skeletogenesis but also benign osteochondral neoplasms or orthotopic lesions of skeletal modeling. The present study provides insight into the genetic basis of osteochondroma formation in patients with fibrodysplasia ossificans progressiva and possibly into that of more common conditions in which these lesions occur.

Entities:  

Mesh:

Year:  2008        PMID: 18245597      PMCID: PMC3516450          DOI: 10.2106/JBJS.G.00774

Source DB:  PubMed          Journal:  J Bone Joint Surg Am        ISSN: 0021-9355            Impact factor:   5.284


  40 in total

1.  In vivo somatic cell gene transfer of an engineered Noggin mutein prevents BMP4-induced heterotopic ossification.

Authors:  David L Glaser; Aris N Economides; Lili Wang; Xia Liu; Robert D Kimble; James P Fandl; James M Wilson; Neil Stahl; Frederick S Kaplan; Eileen M Shore
Journal:  J Bone Joint Surg Am       Date:  2003-12       Impact factor: 5.284

2.  Influenza-like viral illnesses and flare-ups of fibrodysplasia ossificans progressiva.

Authors:  Richard F Scarlett; David M Rocke; Sharon Kantanie; Jean B Patel; Eileen M Shore; Frederick S Kaplan
Journal:  Clin Orthop Relat Res       Date:  2004-06       Impact factor: 4.176

3.  Hereditary multiple exostoses. Anthropometric, roentgenographic, and clinical aspects.

Authors:  F Shapiro; S Simon; M J Glimcher
Journal:  J Bone Joint Surg Am       Date:  1979-09       Impact factor: 5.284

4.  The hand and foot malformations in fibrodysplasia ossificans progressiva.

Authors:  H W Schroeder; M Zasloff
Journal:  Johns Hopkins Med J       Date:  1980-08

5.  Fibrodysplasia ossificans progressiva. A survey of forty-two cases.

Authors:  J G Rogers; W B Geho
Journal:  J Bone Joint Surg Am       Date:  1979-09       Impact factor: 5.284

6.  Surgical treatment of symptomatic osteochondroma. A three- to eight-year follow-up study.

Authors:  F Bottner; R Rodl; I Kordish; W Winklemann; G Gosheger; N Lindner
Journal:  J Bone Joint Surg Br       Date:  2003-11

7.  Fibrodysplasia ossificans progressiva. The clinical features and natural history of 34 patients.

Authors:  J M Connor; D A Evans
Journal:  J Bone Joint Surg Br       Date:  1982

8.  Abrogation of heparan sulfate synthesis in Drosophila disrupts the Wingless, Hedgehog and Decapentaplegic signaling pathways.

Authors:  Douglas J Bornemann; Jason E Duncan; William Staatz; Scott Selleck; Rahul Warrior
Journal:  Development       Date:  2004-03-31       Impact factor: 6.868

9.  ALK2 functions as a BMP type I receptor and induces Indian hedgehog in chondrocytes during skeletal development.

Authors:  Donghui Zhang; Edward M Schwarz; Randy N Rosier; Michael J Zuscik; J Edward Puzas; Regis J O'Keefe
Journal:  J Bone Miner Res       Date:  2003-09       Impact factor: 6.741

10.  Ext1-dependent heparan sulfate regulates the range of Ihh signaling during endochondral ossification.

Authors:  Lydia Koziel; Melanie Kunath; Olivia G Kelly; Andrea Vortkamp
Journal:  Dev Cell       Date:  2004-06       Impact factor: 12.270

View more
  37 in total

1.  Osteochondromas in fibrodysplasia ossificans progressiva: a widespread trait with a streaking but overlooked appearance when arising at femoral bone end.

Authors:  A Morales-Piga; J Bachiller-Corral; P González-Herranz; M Medrano-SanIldelfonso; J Olmedo-Garzón; G Sánchez-Duffhues
Journal:  Rheumatol Int       Date:  2015-06-07       Impact factor: 2.631

2.  Is fibrodysplasia ossificans progressiva ever seen without skeletal abnormalities?

Authors:  Sumeet Gulshan Dua; Nilendu C Purandare
Journal:  Rheumatol Int       Date:  2011-03-25       Impact factor: 2.631

Review 3.  Glycobiology and the growth plate: current concepts in multiple hereditary exostoses.

Authors:  Kevin B Jones
Journal:  J Pediatr Orthop       Date:  2011 Jul-Aug       Impact factor: 2.324

4.  Palovarotene Inhibits Osteochondroma Formation in a Mouse Model of Multiple Hereditary Exostoses.

Authors:  Toshihiro Inubushi; Isabelle Lemire; Fumitoshi Irie; Yu Yamaguchi
Journal:  J Bone Miner Res       Date:  2017-11-30       Impact factor: 6.741

5.  Myositis ossificans in children: a review.

Authors:  N K Sferopoulos; R Kotakidou; A S Petropoulos
Journal:  Eur J Orthop Surg Traumatol       Date:  2017-03-09

Review 6.  Fibrodysplasia ossificans progressiva: Basic understanding and experimental models.

Authors:  Zijuan Qi; Jing Luan; Xiaoyan Zhou; Yazhou Cui; Jinxiang Han
Journal:  Intractable Rare Dis Res       Date:  2017-11

7.  Fibrodysplasia ossificans progressiva (FOP): watch the great toes!

Authors:  Mutlu Kartal-Kaess; Eileen M Shore; Meiqi Xu; Ludwig Schwering; Markus Uhl; Rudolf Korinthenberg; Charlotte Niemeyer; Frederick S Kaplan; Melchior Lauten
Journal:  Eur J Pediatr       Date:  2010-06-26       Impact factor: 3.183

Review 8.  Fibrodysplasia ossificans progressiva (FOP): A disorder of osteochondrogenesis.

Authors:  Frederick S Kaplan; Mona Al Mukaddam; Alexandra Stanley; O Will Towler; Eileen M Shore
Journal:  Bone       Date:  2020-07-27       Impact factor: 4.398

9.  PET/CT of fibrodysplasia ossificans progressiva.

Authors:  Robert Kulwin; Larry A Binkovitz
Journal:  Pediatr Radiol       Date:  2009-05-15

10.  When one skeleton is enough: approaches and strategies for the treatment of fibrodysplasia ossificans progressiva (FOP).

Authors:  Frederick S Kaplan; Jay Groppe; Eileen M Shore
Journal:  Drug Discov Today Ther Strateg       Date:  2008
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.